COVID-19 Vaccine Authorized in India-A Mini Review
Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which is responsible for Coronavirus disease (COVID-19) has spread to 220 countries and has been found to be challenging. Many variants detected after Wuhan-Hu-1 reference which were able to develop the resistance against the neutralizing antibodies induced by vaccine and may cause false negative results in diagnostic tests targeting the S gene. The COVID-19 cases are increasing rapidly in India and the government authorized a new vaccine for restricted use in emergency situation. This review discusses about the efficacy, safety, and economical aspects of vaccines authorized in India. The rAd26-s & rAd5-s (Gamaleya Research Institute of Epidemiology and Microbiology) demonstrate high efficacy as well as safety, followed by BBV152 (Bharat Biotech) and AZD1222 (Oxford AstraZeneca); AZD1222 is more economical than other two
Year of publication: |
[2021]
|
---|---|
Authors: | Shrestha, Yogendra ; Venkataraman, Rajesh ; Moktan, Jeet Bahadur ; Chitti, Renukaradhya ; Yadav, Shiv Kumar |
Publisher: |
[S.l.] : SSRN |
Subject: | Coronavirus | Impfung | Vaccination | Arzneimittel | Pharmaceuticals | Gesundheitspolitik | Health policy | Wirkungsanalyse | Impact assessment | Großbritannien | United Kingdom |
Saved in:
freely available
Extent: | 1 Online-Ressource (13 p) |
---|---|
Type of publication: | Book / Working Paper |
Language: | English |
Notes: | Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments April 29, 2021 erstellt |
Other identifiers: | 10.2139/ssrn.3836545 [DOI] |
Source: | ECONIS - Online Catalogue of the ZBW |
Persistent link: https://www.econbiz.de/10013229285
Saved in favorites
Similar items by subject
-
The hammer and the jab : are COVID-19 lockdowns and vaccinations complements or substitutes?
Caulkins, Jonathan P., (2023)
-
Maleva, T. M., (2021)
-
Does vaccination mitigate the negative impacts of coronavirus on trade?
Hayakawa, Kazunobu, (2021)
- More ...